1177 — Sino Biopharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$85.67bn
- HK$90.92bn
- CNY31.83bn
Sino Biopharmaceutical rises most in nearly 5 weeks on LaNova deal
Brief: 中国生物制药斥1.4亿元取得禮新醫藥4.91%股權，就LM-108在中國大陸戰略合作
Brief: Sino Biopharmaceutical Signs Equity Investment And Strategic Cooperation Agreement
Brief: Sino Biopharmaceutical Says Approval Granted For EGFR Inhibitor "TQB3002"
Brief: Sino Biopharmaceutical Approval For Marketing Of Kras G12c Inhibitor Garsorasib Tablet From Nmpa
Brief: Sino Biopharmaceutical Says Acquisition Of 29.99% Equity Interest In Hob Biotech
Brief: Sino Biopharmaceutical Posts Qtrly Profit Attributable Of RMB1.15 Bln
Brief: Sino Biopharmaceutical Announces Exclusive License And Cooperation Deal With YZY Biopharma
Brief: Sino Biopharmaceutical Announces Interim Dividend Of HK3 Cents Per Share
Brief: Sino Biopharmaceutical Announces Acceptance Of New Drug Application
Sino Biopharm jumps on positive cancer drug trial results
Brief: Sino Biopharmaceutical Says NMPA Acceptance Of NDA For Rovadicitinib (Tq05105)
Sino Biopharm jumps most in 7 weeks on marketing nod for sugar control injection
Brief: Sino Biopharmaceutical Announces Approval For Marketing Of Liraglutide Injection
Brief: Sino Biopharmaceutical Says Envonalkib (TQ-B3139) Got Approval For Marketing From Nmpa Of China
Brief: Sino Biopharmaceutical Says Approval For Marketing Of Gadoteridol Injection From Nmpa
Brief: Sino Biopharmaceutical's Kras G12c Inhibitor Included In Breakthrough Therapeutic Designation
Factbox: Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic
Brief: Sino Biopharmaceutical Says Positive Results On Phase Iii Study Of Benmelstobart Injection